Associated Papers
Leucine-Rich Repeat Kinase 2: Pathways to Parkinson's Disease.
Pfeffer SR et al.
Cold Spring Harbor Perspectives in Medicine, 2025
Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study.
Westenberger A et al.
Brain : a Journal of Neurology, 2024
LRRK2 exonic variants are associated with lysosomal hydrolase activities and lysosphingolipid alterations in Parkinson's disease.
Usenko TS et al.
Gene, 2023
Precision Medicine in Parkinson's Disease: From Genetic Risk Signals to Personalized Therapy.
Straccia G et al.
Brain Sciences, 2022
Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding.
Kalogeropulou AF et al.
The Biochemical Journal, 2022
The Role of Genetic Data in Selecting Device-Aided Therapies in Patients With Advanced Parkinson's Disease: A Mini-Review.
Chan GH
Frontiers in Aging Neuroscience, 2022
Deep brain stimulation in Early Onset Parkinson's disease.
Krause P et al.
Frontiers in Neurology, 2022
Oxidative stress factors in Parkinson's disease.
Dorszewska J et al.
Neural Regeneration Research, 2021
Deep brain stimulation for monogenic Parkinson's disease: a systematic review.
Kuusimäki T et al.
Journal of Neurology, 2020
LRRK2 Phosphorylation, More Than an Epiphenomenon.
Marchand A et al.
Frontiers in Neuroscience, 2020
Genetic background and outcome of Deep Brain Stimulation in Parkinson's disease.
Rizzone MG et al.
Parkinsonism & Related Disorders, 2019
Deep Brain Stimulation in Patients With Mutations in Parkinson's Disease-Related Genes: A Systematic Review.
de Oliveira LM et al.
Movement Disorders Clinical Practice, 2019
Association of Subthalamic Deep Brain Stimulation With Motor, Functional, and Pharmacologic Outcomes in Patients With Monogenic Parkinson Disease: A Systematic Review and Meta-analysis.
Artusi CA et al.
Jama Network Open, 2019
Deep brain stimulation and genetic variability in Parkinson's disease: a review of the literature.
Ligaard J et al.
Npj Parkinson's Disease, 2019
Functional and behavioral consequences of Parkinson's disease-associated LRRK2-G2019S mutation.
Benson DL et al.
Biochemical Society Transactions, 2018
Rab29 activation of the Parkinson's disease-associated LRRK2 kinase.
Purlyte E et al.
The Embo Journal, 2018
Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.
Monfrini E et al.
Advances in Neurobiology, 2017
Structural and functional in silico analysis of LRRK2 missense substitutions.
Cardona F et al.
Molecular Biology Reports, 2014
Lack of correlation between the kinase activity of LRRK2 harboring kinase-modifying mutations and its phosphorylation at Ser910, 935, and Ser955.
Ito G et al.
Plos One, 2014
In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2.
Vancraenenbroeck R et al.
Frontiers in Molecular Neuroscience, 2014
Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease.
Greggio E
Biochemical Society Transactions, 2012
Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.
Kramer T et al.
Acs Chemical Neuroscience, 2012
Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition.
Doggett EA et al.
Journal of Neurochemistry, 2012
Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study.
Ross OA et al.
The Lancet. Neurology, 2011
14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization.
Nichols RJ et al.
The Biochemical Journal, 2010
Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization.
Dzamko N et al.
The Biochemical Journal, 2010
Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update.
Nuytemans K et al.
Human Mutation, 2010
Identification of four novel potentially Parkinson's disease associated LRRK2 variations among Iranian patients.
Shojaee S et al.
Neuroscience Letters, 2009
LRRK2 in Parkinson's disease: genetic and clinical studies from patients.
Kumari U et al.
The Febs Journal, 2009
LRRK2 gene variation and its contribution to Parkinson disease.
Paisán-Ruiz C
Human Mutation, 2009
Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease.
Biskup S et al.
Biochimica Et Biophysica Acta, 2009
Molecular analyses of the LRRK2 gene in European and North African autosomal dominant Parkinson's disease.
Lesage S et al.
Journal of Medical Genetics, 2009
Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.
Gandhi PN et al.
Journal of Neuroscience Research, 2009
Parkinson's disease: from monogenic forms to genetic susceptibility factors.
Lesage S et al.
Human Molecular Genetics, 2009
Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls.
Paisán-Ruíz C et al.
Human Mutation, 2008
Outcome of bilateral deep brain subthalamic stimulation in patients carrying the R1441G mutation in the LRRK2 dardarin gene.
Gómez-Esteban JC et al.
Neurosurgery, 2008
Mutations in LRRK2 as a cause of Parkinson's disease.
Giasson BI et al.
Neuro-signals, 2008
LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans.
Lesage S et al.
Archives of Neurology, 2007
Subthalamic nucleus stimulation is efficacious in patients with Parkinsonism and LRRK2 mutations.
Schüpbach M et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2007